Malin (DUB:MLC) Treasury Stock : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Malin Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Malin's treasury stock for the quarter that ended in Dec. 2023 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Malin Treasury Stock Historical Data

The historical data trend for Malin's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Malin Treasury Stock Chart

Malin Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

Malin Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Treasury Stock	Get a 7-Day Free Trial													-	-	-	-	-

Malin Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Malin (DUB:MLC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (DUB:MLC) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

0Y71:UK

Address

50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02

Website

http://www.malinplc.com

Malin Corporation PLC is a global life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. Its subsidiary income is derived from the sale of pharmaceutical products.

Malin (DUB:MLC) Headlines

No Headlines